Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

The safety of belimumab for the treatment of systemic lupus erythematosus.

Wise LM, Stohl W.

Expert Opin Drug Saf. 2019 Dec;18(12):1133-1144. doi: 10.1080/14740338.2019.1685978. Epub 2019 Oct 31.

PMID:
31657965
2.

Development of murine systemic lupus erythematosus in the absence of BAFF.

Stohl W, Yu N, Chalmers S, Putterman C, Jacob CO.

Arthritis Rheumatol. 2019 Sep 7. doi: 10.1002/art.41097. [Epub ahead of print]

PMID:
31493335
3.

Constitutive reduction in the checkpoint inhibitor, CTLA-4, does not accelerate SLE in NZM 2328 mice.

Stohl W, Yu N, Chalmers SA, Putterman C, Jacob CO.

Lupus Sci Med. 2019 Feb 19;6(1):e000313. doi: 10.1136/lupus-2018-000313. eCollection 2019.

4.

Elevated serum globulin gap as a highly reliable marker of elevated erythrocyte sedimentation rate in patients with systemic rheumatic diseases.

Stohl W, Kenol B, Kelly AJ, Ananth Correa A, Panush RS.

Semin Arthritis Rheum. 2019 Dec;49(3):485-492. doi: 10.1016/j.semarthrit.2019.05.001. Epub 2019 May 11.

PMID:
31153707
5.

IgM Plasma Cells Reside in Healthy Skin and Accumulate with Chronic Inflammation.

Wilson RP, McGettigan SE, Dang VD, Kumar A, Cancro MP, Nikbakht N, Stohl W, Debes GF.

J Invest Dermatol. 2019 Dec;139(12):2477-2487. doi: 10.1016/j.jid.2019.05.009. Epub 2019 May 30.

PMID:
31152755
6.

Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus.

Wallace DJ, Ginzler EM, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Petri M, Fettiplace J, Roth DA, Ji B, Heath A.

Arthritis Rheumatol. 2019 Jul;71(7):1125-1134. doi: 10.1002/art.40861. Epub 2019 Jun 5.

7.

Clinical response beyond the Systemic Lupus Erythematosus Responder Index: post-hoc analysis of the BLISS-SC study.

van Vollenhoven RF, Stohl W, Furie RA, Fox NL, Groark JG, Bass D, Kurtinecz M, Pobiner BF, Eastman WJ, Gonzalez-Rivera T, Gordon D.

Lupus Sci Med. 2018 Nov 26;5(1):e000288. doi: 10.1136/lupus-2018-000288. eCollection 2018.

8.

Increased Cathepsin S activity associated with decreased protease inhibitory capacity contributes to altered tear proteins in Sjögren's Syndrome patients.

Edman MC, Janga SR, Meng Z, Bechtold M, Chen AF, Kim C, Naman L, Sarma A, Teekappanavar N, Kim AY, Madrigal S, Singh S, Ortiz E, Christianakis S, Arkfeld DG, Mack WJ, Heur M, Stohl W, Hamm-Alvarez SF.

Sci Rep. 2018 Jul 23;8(1):11044. doi: 10.1038/s41598-018-29411-9.

9.

A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.

Doria A, Bass D, Schwarting A, Hammer A, Gordon D, Scheinberg M, Fox NL, Groark J, Stohl W, Kleoudis C, Roth D.

Lupus. 2018 Aug;27(9):1489-1498. doi: 10.1177/0961203318777634. Epub 2018 May 28.

10.

Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus.

Doria A, Stohl W, Schwarting A, Okada M, Scheinberg M, van Vollenhoven R, Hammer AE, Groark J, Bass D, Fox NL, Roth D, Gordon D.

Arthritis Rheumatol. 2018 Aug;70(8):1256-1264. doi: 10.1002/art.40511. Epub 2018 Jun 15.

11.

Maternal Serum B-Cell Activating Factor Levels: Candidate Early Biomarker for Hypertensive Disorders of Pregnancy.

Stohl HE, Lee RH, Manetta J, Kikly K, Korst LM, Stohl W.

Hypertension. 2017 Nov;70(5):1007-1013. doi: 10.1161/HYPERTENSIONAHA.117.09775. Epub 2017 Sep 18.

PMID:
28923901
12.

Systemic lupus erythematosus: BAFF emerges from the genetic shadows.

Stohl W.

Nat Rev Rheumatol. 2017 Aug;13(8):456-457. doi: 10.1038/nrrheum.2017.99. Epub 2017 Jun 15. No abstract available.

PMID:
28615729
13.

A TLR9-dependent checkpoint governs B cell responses to DNA-containing antigens.

Sindhava VJ, Oropallo MA, Moody K, Naradikian M, Higdon LE, Zhou L, Myles A, Green N, Nündel K, Stohl W, Schmidt AM, Cao W, Dorta-Estremera S, Kambayashi T, Marshak-Rothstein A, Cancro MP.

J Clin Invest. 2017 May 1;127(5):1651-1663. doi: 10.1172/JCI89931. Epub 2017 Mar 27.

14.

Inhibition of B cell activating factor (BAFF) in the management of systemic lupus erythematosus (SLE).

Stohl W.

Expert Rev Clin Immunol. 2017 Jun;13(6):623-633. doi: 10.1080/1744666X.2017.1291343. Epub 2017 Feb 15. Review.

PMID:
28164726
15.

Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.

Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, Kleoudis C, Groark J, Bass D, Fox NL, Roth D, Gordon D.

Arthritis Rheumatol. 2017 May;69(5):1016-1027. doi: 10.1002/art.40049. Epub 2017 Apr 7.

16.

Serum progranulin levels in Hispanic rheumatoid arthritis patients treated with TNF antagonists: a prospective, observational study.

Johnson J, Yeter K, Rajbhandary R, Neal R, Tian Q, Jian J, Fadle N, Thurner L, Liu C, Stohl W.

Clin Rheumatol. 2017 Mar;36(3):507-516. doi: 10.1007/s10067-016-3467-7. Epub 2016 Nov 9.

PMID:
27830341
17.

B cell-independent contribution of BAFF to murine autoimmune disease.

Stohl W, Banfalvi A.

Clin Immunol. 2016 Nov;172:111-116. doi: 10.1016/j.clim.2016.07.009. Epub 2016 Jul 16.

PMID:
27430521
18.

Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Merrill JT, van Vollenhoven RF, Buyon JP, Furie RA, Stohl W, Morgan-Cox M, Dickson C, Anderson PW, Lee C, Berclaz PY, Dörner T.

Ann Rheum Dis. 2016 Feb;75(2):332-40. doi: 10.1136/annrheumdis-2015-207654. Epub 2015 Aug 20.

PMID:
26293163
19.

Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials.

Stohl W, Merrill JT, Looney RJ, Buyon J, Wallace DJ, Weisman MH, Ginzler EM, Cooke B, Holloway D, Kaliyaperumal A, Kuchimanchi KR, Cheah TC, Rasmussen E, Ferbas J, Belouski SS, Tsuji W, Zack DJ.

Arthritis Res Ther. 2015 Aug 20;17:215. doi: 10.1186/s13075-015-0741-z.

20.

Differential Development of Systemic Lupus Erythematosus in NZM 2328 Mice Deficient in Discrete Pairs of BAFF Receptors.

Jacob CO, Yu N, Sindhava V, Cancro MP, Pawar RD, Putterman C, Stohl W.

Arthritis Rheumatol. 2015 Sep;67(9):2523-35. doi: 10.1002/art.39210.

21.

A dendritic-cell-stromal axis maintains immune responses in lymph nodes.

Kumar V, Dasoveanu DC, Chyou S, Tzeng TC, Rozo C, Liang Y, Stohl W, Fu YX, Ruddle NH, Lu TT.

Immunity. 2015 Apr 21;42(4):719-30. doi: 10.1016/j.immuni.2015.03.015.

22.

Editorial: the BAFFling immunology of systemic lupus erythematosus: beyond B cells.

Stohl W.

Arthritis Rheumatol. 2015 Mar;67(3):612-5. doi: 10.1002/art.38951. No abstract available.

23.

Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fcγ receptor IIb inhibitory receptor.

Chu SY, Yeter K, Kotha R, Pong E, Miranda Y, Phung S, Chen H, Lee SH, Leung I, Bonzon C, Desjarlais JR, Stohl W, Szymkowski DE.

Arthritis Rheumatol. 2014 May;66(5):1153-64. doi: 10.1002/art.38334.

24.

Tear cathepsin S as a candidate biomarker for Sjögren's syndrome.

Hamm-Alvarez SF, Janga SR, Edman MC, Madrigal S, Shah M, Frousiakis SE, Renduchintala K, Zhu J, Bricel S, Silka K, Bach D, Heur M, Christianakis S, Arkfeld DG, Irvine J, Mack WJ, Stohl W.

Arthritis Rheumatol. 2014 Jul;66(7):1872-81. doi: 10.1002/art.38633.

25.

Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus.

Stohl W.

Expert Opin Ther Targets. 2014 Apr;18(4):473-89. doi: 10.1517/14728222.2014.888415. Epub 2014 Feb 13. Review.

PMID:
24521424
26.

APRIL mediates peritoneal B-1 cell homeostasis.

Sindhava VJ, Scholz JL, Stohl W, Cancro MP.

Immunol Lett. 2014 Aug;160(2):120-7. doi: 10.1016/j.imlet.2014.01.018. Epub 2014 Feb 7.

27.

Local BLyS production by T follicular cells mediates retention of high affinity B cells during affinity maturation.

Goenka R, Matthews AH, Zhang B, O'Neill PJ, Scholz JL, Migone TS, Leonard WJ, Stohl W, Hershberg U, Cancro MP.

J Exp Med. 2014 Jan 13;211(1):45-56. doi: 10.1084/jem.20130505. Epub 2013 Dec 23.

28.

Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.

Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA; LBSL02/99 Study Group.

J Rheumatol. 2014 Feb;41(2):300-9. doi: 10.3899/jrheum.121368. Epub 2013 Nov 1.

29.

Future prospects in biologic therapy for systemic lupus erythematosus.

Stohl W.

Nat Rev Rheumatol. 2013 Dec;9(12):705-20. doi: 10.1038/nrrheum.2013.136. Epub 2013 Sep 10. Review.

PMID:
24018550
30.

BAFF- and APRIL-dependent maintenance of antibody titers after immunization with T-dependent antigen and CD1d-binding ligand.

Shah HB, Joshi SK, Rampuria P, Devera TS, Lang GA, Stohl W, Lang ML.

J Immunol. 2013 Aug 1;191(3):1154-63. doi: 10.4049/jimmunol.1300263. Epub 2013 Jun 24.

31.

Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study.

Stohl W, Merrill JT, McKay JD, Lisse JR, Zhong ZJ, Freimuth WW, Genovese MC.

J Rheumatol. 2013 May;40(5):579-89. doi: 10.3899/jrheum.120886. Epub 2013 Apr 1.

PMID:
23547209
32.

Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor.

Jacob CO, Yu N, Guo S, Jacob N, Quinn WJ 3rd, Sindhava V, Cancro MP, Goilav B, Putterman C, Migone TS, Stohl W.

Arthritis Rheum. 2013 Apr;65(4):1043-54. doi: 10.1002/art.37846.

33.

Racial/ethnic differences in the use of biologic disease-modifying antirheumatic drugs among California Medicaid rheumatoid arthritis patients.

Chu LH, Portugal C, Kawatkar AA, Stohl W, Nichol MB.

Arthritis Care Res (Hoboken). 2013 Feb;65(2):299-303. doi: 10.1002/acr.21798.

34.

Induced T regulatory cells suppress osteoclastogenesis and bone erosion in collagen-induced arthritis better than natural T regulatory cells.

Kong N, Lan Q, Su W, Chen M, Wang J, Yang Z, Park R, Dagliyan G, Conti PS, Brand D, Liu Z, Stohl W, Zou H, Zheng SG.

Ann Rheum Dis. 2012 Sep;71(9):1567-1572. doi: 10.1136/annrheumdis-2011-201052. Epub 2012 Jul 4.

35.

Incremental expenditure of biologic disease modifying antirheumatic treatment using instrumental variables in panel data.

Kawatkar AA, Hay JW, Stohl W, Nichol MB.

Health Econ. 2013 Jul;22(7):807-23. doi: 10.1002/hec.2855. Epub 2012 Jun 21.

PMID:
22718267
36.

Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial.

Chatham WW, Wallace DJ, Stohl W, Latinis KM, Manzi S, McCune WJ, Tegzová D, McKay JD, Avila-Armengol HE, Utset TO, Zhong ZJ, Hough DR, Freimuth WW, Migone TS; BLISS-76 Study Group.

J Rheumatol. 2012 Aug;39(8):1632-40. Epub 2012 Jun 15.

37.
38.

Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial.

Stohl W, Gomez-Reino J, Olech E, Dudler J, Fleischmann RM, Zerbini CA, Ashrafzadeh A, Grzeschik S, Bieraugel R, Green J, Francom S, Dummer W.

Ann Rheum Dis. 2012 Aug;71(8):1289-96. doi: 10.1136/annrheumdis-2011-200706. Epub 2012 Feb 2.

39.

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.

Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, Aranow C, Wellborne FR, Abud-Mendoza C, Hough DR, Pineda L, Migone TS, Zhong ZJ, Freimuth WW, Chatham WW; BLISS-52 Study Group; BLISS-76 Study Group.

Arthritis Rheum. 2012 Jul;64(7):2328-37. doi: 10.1002/art.34400.

40.

The discovery and development of belimumab: the anti-BLyS-lupus connection.

Stohl W, Hilbert DM.

Nat Biotechnol. 2012 Jan 9;30(1):69-77. doi: 10.1038/nbt.2076.

41.

Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice.

Jacob CO, Guo S, Jacob N, Pawar RD, Putterman C, Quinn WJ 3rd, Cancro MP, Migone TS, Stohl W.

Arthritis Rheum. 2012 May;64(5):1610-9. doi: 10.1002/art.33458.

42.

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF; BLISS-76 Study Group.

Arthritis Rheum. 2011 Dec;63(12):3918-30. doi: 10.1002/art.30613.

43.

Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.

Tak PP, Rigby W, Rubbert-Roth A, Peterfy C, van Vollenhoven RF, Stohl W, Healy E, Hessey E, Reynard M, Shaw T.

Ann Rheum Dis. 2012 Mar;71(3):351-7. doi: 10.1136/annrheumdis-2011-200170. Epub 2011 Oct 19.

44.

BAFF promotes Th17 cells and aggravates experimental autoimmune encephalomyelitis.

Zhou X, Xia Z, Lan Q, Wang J, Su W, Han YP, Fan H, Liu Z, Stohl W, Zheng SG.

PLoS One. 2011;6(8):e23629. doi: 10.1371/journal.pone.0023629. Epub 2011 Aug 29.

45.

Cytokine disturbances in systemic lupus erythematosus.

Jacob N, Stohl W.

Arthritis Res Ther. 2011 Jul 6;13(4):228. doi: 10.1186/ar3349. Review.

46.

B Cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice.

Jacob N, Guo S, Mathian A, Koss MN, Gindea S, Putterman C, Jacob CO, Stohl W.

J Immunol. 2011 Apr 15;186(8):4984-93. doi: 10.4049/jimmunol.1000466. Epub 2011 Mar 7.

47.

Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus.

Horton HM, Chu SY, Ortiz EC, Pong E, Cemerski S, Leung IW, Jacob N, Zalevsky J, Desjarlais JR, Stohl W, Szymkowski DE.

J Immunol. 2011 Apr 1;186(7):4223-33. doi: 10.4049/jimmunol.1003412. Epub 2011 Feb 28.

48.

Targeting BLyS in rheumatic disease: the sometimes-bumpy road from bench to bedside.

Stohl W, Scholz JL, Cancro MP.

Curr Opin Rheumatol. 2011 May;23(3):305-10. doi: 10.1097/BOR.0b013e328344c15e. Review.

49.

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial.

Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W, Hessey E, Chen A, Tyrrell H, Shaw TM; IMAGE Investigators.

Ann Rheum Dis. 2011 Jan;70(1):39-46. doi: 10.1136/ard.2010.137703. Epub 2010 Oct 11.

PMID:
20937671
50.

Supplemental Content

Support Center